Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

Rhea-AI Summary

Revolution Medicines, a clinical-stage oncology company focused on targeted therapies for RAS-addicted cancers, will feature CEO Mark A. Goldsmith in a fireside chat at the 22nd Annual Needham Healthcare Conference from April 17-20, 2023. The chat is scheduled for 3:00 p.m. Eastern on April 20, 2023, and will be held virtually with a webcast available. Interested parties can access the live presentation and the subsequent replay on the company’s website for at least 14 days after the event.

The company specializes in developing RAS(ON) Inhibitors aimed at various oncogenic RAS protein variants, with RMC-6236 and RMC-6291 currently in clinical development. Additional pipeline candidates target other RAS mutations and include RAS Companion Inhibitors for combination therapies. For further details, visit Revolution Medicines Events.

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be the featured speaker in a fireside chat at the 22^nd Annual Needham Healthcare Conference. The conference will take place April 17-20, 2023.

Details of the company’s participation are as follows:

• 22^nd Annual Needham Healthcare Conference
  Conference Dates: April 17-20, 2023
  Fireside Chat Time/Date: 3:00 p.m. Eastern on Thursday, April 20, 2023
  Format: Virtual conference; webcast available

To access the live webcast of the presentation, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS^MULTI) and RMC-6291(KRAS^G12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRAS^G12D) and RMC-0708 (KRAS^Q61H), both of which are currently in IND-enabling development, RMC-8839 (KRAS^G13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

When will Revolution Medicines present at the 22nd Annual Needham Healthcare Conference?

Revolution Medicines will present at the conference from April 17-20, 2023, with the fireside chat scheduled for 3:00 p.m. Eastern on April 20, 2023.

How can I access the webcast for Revolution Medicines' presentation?

You can access the live webcast on the 'Events & Presentations' page of Revolution Medicines’ website.

What therapies is Revolution Medicines developing for RAS-addicted cancers?

Revolution Medicines is developing RAS(ON) Inhibitors and RAS Companion Inhibitors targeting various oncogenic RAS variants.

What are some of the RAS(ON) Inhibitors in Revolution Medicines' pipeline?

Key RAS(ON) Inhibitors in development include RMC-6236, RMC-6291, RMC-9805, and RMC-0708.

Will a replay of the Revolution Medicines presentation be available?

Yes, a replay of the webcast will be available for at least 14 days following the conference.